Roche Holding AG


  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • US pulls approval for these Nexium, Valcyte generics Thursday, 6 Nov 2014 | 9:47 AM ET

    The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.

  • *Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte. *FDA said approvals were given "in error"- Ranbaxy. The FDA has also stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow to the Indian company that has been hit by a raft of regulatory bans over poor production quality.

  • Alibaba’s market value surpasses Wal-Mart Tuesday, 28 Oct 2014 | 8:27 PM ET
    An employee walks past the Alibaba logo during a media tour organized by government officials at the company’s headquarters outside of Hangzhou, Zhejiang province, China.

    Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.

  • Drugmakers double down on Ebola vaccines, treatments Monday, 27 Oct 2014 | 7:31 AM ET
    People participate in a march, organized by New York’s West African community, to end Ebola, Oct. 24, 2014, in New York.

    Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...

  • US STOCKS-Futures lower as weak IBM earnings weigh Monday, 20 Oct 2014 | 8:04 AM ET

    *IBM slumps after quarterly results. NEW YORK, Oct 20- U.S. stock index futures were lower on Monday, on the heels of a fourth week of losses for the benchmark S&P 500, as quarterly results from IBM disappointed. IBM shares slumped 7 percent to $169.24 as the most actively traded stock on the New York Stock Exchange in premarket after the company's third-quarter...

  • Oct 20- NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments. NewLink's shares jumped nearly 26 percent before the bell on Monday. Immunotherapies are a class of drugs designed to help the...

  • WASHINGTON, Oct 16- Medicine costs would rise if draft proposals in a Pacific Rim trade pact come into force, health and consumer rights advocates said on Thursday after the release of a leaked negotiating text. The TPP's 12 members range from the United States and Japan to Malaysia and Vietnam, where equitable access to medicine is a priority, and Australia and...

  • Europe closes off lows, Greek bond yields near 9% Thursday, 16 Oct 2014 | 11:49 AM ET

    European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.

  • Roche sales beat forecasts, confirms outlook Thursday, 16 Oct 2014 | 3:34 AM ET

    Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.

  • We're not looking at mega-mergers: Roche CEO  Thursday, 16 Oct 2014 | 2:45 AM ET

    Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.

  • Roche CEO on Ebola outbreak  Thursday, 16 Oct 2014 | 2:45 AM ET

    Severin Schwan, CEO of Roche Group, says the world was surprised by the "magnitude" of the Ebola outbreak.

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...

  • Oct 15- The U.S. Food and Drug Administration approved two drugs to treat idiopathic pulmonary fibrosis, marking its first-ever approvals for the fatal lung disease with no clear etiology and no cure. Roche Holding AG's Esbriet, which is already in use in Europe and Canada, and privately held German drugmaker Boehringer Ingelheim's Ofev both received the...

  • Going in through back door for M&A deal profits Friday, 3 Oct 2014 | 8:00 AM ET

    Mergers have hit a level not seen since the financial crisis, and there is a way for investors to profit from the M&A frenzy—in one trade.

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Cancer drug stocks on the move amid striking data Monday, 29 Sep 2014 | 11:14 AM ET

    Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.